Neoplasms

All Conditions

Rare Diseases

Carcinoma

Sarcoma

Soft Tissue Sarcoma

dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.

darinaparsin

Jonathan J. Lewis, MD, PhD

This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.

Study of Oral Darinaparsin in Patients With Advanced Solid Tumors

Phase I Study of Oral Darinaparsin in Advanced Solid Tumors

a primary outcome measure is to determine the toxicity profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

a primary outcome measure is to determine the maximum tolerated dose of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

a primary outcome measure is to determine the preliminary activity/efficacy of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

a primary outcome measure is to determine the pharmacokinetic profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

Alaunos Therapeutics

Blood and Lymph Conditions

Immune System Diseases

Lymphoma

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Anti-Inflammatory Agents

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Prednisone

Vincristine

I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.

Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.

CHOP

This study is a Phase I trial of Darinaparsin in combination with CHOP for the treatment of lymphoma. Eligible patients will not have had any previous anti-cancer treatment and will be eligible to receive CHOP alone.

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

A Phase I Dose Escalation Study of Darinaparsin in Combination With CHOP in Previously Untreated Patients With Lymphomas Who Are Scheduled to Receive CHOP Alone

This is an open-label, dose-escalation Phase I study to define the toxicity profile and the maximum tolerated dose (MTD) of intravenously administered darinaparsin in combination with CHOP in patients with previously untreated lymphomas who are scheduled to receive CHOP alone (rituximab is not permitted)

This is an open-label, dose-escalation Phase I study to define the toxicity profile and the maximum tolerated dose (MTD) of intravenously administered darinaparsin in combination with CHOP in patients with previously untreated lymphomas who are scheduled to receive CHOP alone (rituximab is not permitted).

Digestive System Diseases

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months

Darinaparsin

The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Hematologic Neoplasms

Bone Marrow Neoplasms

Hematologic Diseases

Bone Marrow Diseases

Peripheral T-cell Lymphoma

300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.

The study of safety of a new organic arsenic compound in the treatment of hematological malignancies.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors	NCT01139346	Advanced Solid ...	darinaparsin	18 Years -	Alaunos Therapeutics
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma	NCT01139359	Lymphoma	darinaparsin CHOP	18 Years -	Alaunos Therapeutics
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma	NCT00423306	HEPATOCELLULAR ...	Darinaparsin	18 Years -	Alaunos Therapeutics
Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma	NCT01139359	Lymphoma	darinaparsin CHOP	18 Years -	Alaunos Therapeutics
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers	NCT00421213	Hematologic Neo... Bone Marrow Neo... Non-Hodgkin's L...	Darinaparsin	18 Years -	Alaunos Therapeutics
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers	NCT00421213	Hematologic Neo... Bone Marrow Neo... Non-Hodgkin's L...	Darinaparsin	18 Years -	Alaunos Therapeutics
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors	NCT01139346	Advanced Solid ...	darinaparsin	18 Years -	Alaunos Therapeutics
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors	NCT01139346	Advanced Solid ...	darinaparsin	18 Years -	Alaunos Therapeutics

Spots Global Cancer Trial Database for darinaparsin

Every month we try and update this database with for darinaparsin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.